DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0124697 A1 Evans Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0124697 A1 Evans Et Al US 2005O124697A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0124697 A1 Evans et al. (43) Pub. Date: Jun. 9, 2005 (54) NSAID-CONTAINING TOPICAL Publication Classification FORMULATIONS THAT DEMONSTRATE CHEMOPREVENTIVE ACTIVITY (51) Int. Cl." ............................................ A61K 31/192 (52) U.S. Cl. ............................................ 514/569; 514/570 (75) Inventors: Allan Evans, Rosslyn Park (AU); Ross McKinnon, Aberfoyle Park (AU) (57) ABSTRACT Correspondence Address: HOGAN & HARTSON LLP Disclosed herein are chemopreventive methods and topical IP GROUP, COLUMBIA SQUARE formulations for the prevention and treatment of ultraviolet 555 THIRTEENTH STREET, N.W. light-induced skin cancers, pre-cancerous lesions, and WASHINGTON, DC 20004 (US) hyperproliferative disorders in mammals, Such as humans, utilizing doses of non-Steroidal anti-inflammatory drugs. (73) Assignee: PharmaChest Pty Ltd Low doses of non-Steroidal anti-inflammatory drugs are present in the topical formulations and allow continued (21) Appl. No.: 11/037,260 regular use over an extended period of time to prevent Such (22) Filed: Jan. 19, 2005 disorders. In particular, the present invention is particularly Suitable for non-melanoma skin cancers as these cancers Related U.S. Application Data tend to appear in areas of the skin that have had exceSS Sun exposure (head, neck and arms) meaning that the chemo (62) Division of application No. 10/310,824, filed on Dec. preventive agent would not need to be applied over the entire 6, 2002. body of the typical patient. Moreover, it is possible to identify “high-risk” individuals within the populations (60) Provisional application No. 60/350,957, filed on Jan. because people who report one episode of NMSC tend to 25, 2002. have a high incidence of a Subsequent episode. Patent Application Publication Jun. 9, 2005 Sheet 1 of 7 US 2005/0124697 A1 O (M) O O C 0 O ) C () O E O C. O O O C. g O OG og O * O C. O)5 0 D C) s 5 0 ) < H 0 (EO< SEO) : E 0 (g D Z () O () ) D D D D Nu N. N vm SC S S S3 SS SS L. C. S. CN O. O. v. CN of 0 O C. O V L? V r of of GN CN v v. eSnou Jed Sunoun Snid Seuode US 2005/0124697 A1 ETFE?E Snoun + Seuoided Jo Jequn N Patent Applica tion Pub ication Jun. 9, 2005 Sheet 3 of 7 US 2005/0124697 A1 Patent Application Publication Jun. 9, 2005 Sheet 4 of 7 US 2005/0124697 A1 Patent Application Publication Jun. 9, 2005 Sheet 5 of 7 US 2005/0124697 A1 Patent Application Publication Jun. 9, 2005 Sheet 6 of 7 US 2005/0124697 A1 Patent Application Publication Jun. 9, 2005 Sheet 7 of 7 US 2005/0124697 A1 O V V i s O O. O. O. O. O. O. O. O. O. O O O OO N CO RO r C. CN vam vo Ouluoto go efóeueoue. US 2005/O124697 A1 Jun. 9, 2005 NSAID-CONTAINING TOPCAL FORMULATIONS 0008) Notably, 75% of all skin cancers are basal cell THAT DEMONSTRATE CHEMOPREVENTIVE carcinomas (“BCC”). Recent population studies in Australia ACTIVITY indicate incidence rates of between 1-2% for BCC. For CROSS REFERENCE TO RELATED example, the incidence rate in South eastern Queensland in APPLICATIONS particular for those aged 20-69 years was found to be 2.4%. In South Wales in 1998 the incidence of BCC in individuals 0001. This application claims benefit of priority from the over 75 years of age was approximately 5 times higher that filing date of U.S. provisional patent application Ser. No. that of individuals between 50 and 55 years old indicating an 60/350,957, filed Jan. 25, 2002. age related relationship. FIELD OF THE INVENTION 0009. In 1994, the incidence rate of BCC in America was 0002 The present invention relates to the prevention and calculated to be 0.3% with rates increasing at over 10% per treatment of Skin cancer and hyperproliferative Skin disor year with a lifetime risk of up to 30%. It is currently ders in mammals, including humans, with the use of topical projected by Some investigators that, given current rates, 1 medicaments. More particularly, the present invention in every 5 Americans will develop a skin cancer of Some Sort relates to the prevention and treatment of non-melanoma during their lifetime. skin cancers with topical medicaments that are Safe for continued use in target populations. 0010 Thus, NMSC, and BCC in particular, present a Significant health risk throughout the World and generate BACKGROUND Significant health care costs. 0.003 Skin cancer is one of the most frequently diagnosed cancers among the Western populations. Exposure to ultra 0011. Once a patient is diagnosed as having a BCC, the violet light (UV light) is widely acknowledged to be the risk of developing a new BCC is highest in the first year major etiologic factor in the development of Skin cancers thereafter. A recent analysis by Marcil and Stern, published Such as Squamous and basal cell carcinomas, and it is also in Archives of Dermatology in 2000, of the data collected in a risk factor for the development of melanomas. UV light 7 published studies has established that the 3-year cumula has also been found in various Studies to cause inflammation tive risk for developing a Subsequent BCC after the diag of the skin, epidermal hyperplasia, and changes in the nosis of a first BCC is 44% on average. Thus, a perSon once expression of numerous genes associated with cell prolif diagnosed as having a BCC can be considered to be part of eration and differentiation, eicosanoid and cytokine produc a high-risk population for developing new BCCs. Increases tion, and growth factor Synthesis and responsiveness. in risk for Subsequent development of Squamous cell carci nomas was also found. There is also a strong association 0004. An examination of the incidence of non-melanoma between the risk of developing a Subsequent skin cancer and skin cancer (“NMSC"), which includes squamous and basal the number of prior Skin tumours. In one Study the risk was cell carcinomas, indicates that it is a disease associated with increased from 38% for patients with fewer than 3 previous Significant morbidity and which generally requires Surgical NMSCs to 93% for patients with 3 to 9 previous NMSCs. intervention and costly medical care. Thus, the more prior Skin cancers a patient has had, the 0005 NMSC is the most common type of cancer for higher the risk is that that patient will develop skin cancers males and females in the white population, with most NMSC in the future. occurring in people over 40 years of age. People with light 0012 Although the use of physical and chemical Sun complexions, fair or red hair and who tend to burn easily on Screens plays an important role in protection of humans exposure to the Sun (Fitzpatrick skin grades 1 and 2) are against exposure to UV light, the high incidence of skin more prone to develop NMSCs than those with dark-skin. cancer among the population means that additional preven Males have been identified to be at higher risk. Recently, tion and treatment Strategies need to be developed. In Studies have Suggested that heavy exposure to the Sun in the particular, a Safe and effective preventive Strategy is needed first few decades of life may be of the greatest importance for use by those individuals who are most susceptible to this in determining risk. life-threatening disease. 0006 Incidence rates for NMSC in Australia are believed to be the highest in the world with a causal relationship with 0013 The use of specific natural or synthetic agents excessive exposure to Solar ultraViolet radiation. The Aus (usually non-cytotoxic) to reverse, Suppress or prevent can tralian Bureau of Statistics indicates approximately 270,000 cer is referred to as “cancer chemoprevention.” An ideal annual diagnoses of NMSC, which equates to approximately chemopreventive agent should not only be effective, but it 1.5% of the Australian population. It should be noted, should be Safe enough to be used in a target population however, that not all NMSCs are often reported to cancer without causing unnecessary or unacceptable toxicity. It is registries. Thus, it is likely that the number of actual annual important that the perceived benefit (lower risk of cancer) cases of NMSC is significantly higher. The incidence of should be balanced by its safety profile (low risk of adverse NMSC in white populations increases proportionally with events). Agents that have been found in Studies to hold proximity to the equator. In 1993-94 the direct cost of promise for cancer chemoprevention include Vitamin A and treatment of non-melanoma skin cancer in Australia was green tea for skin cancer and tamoxifen and raloxifene for estimated by the NSW Cancer Center at around S232 breast cancer. One group of drugs that has also been million-much more than any other cancer. researched as potential chemopreventive agents are the non-steroidal anti-inflammatory drugs ("NSAIDs"). 0007 Likewise, NMSC constitute more than one third of all cancers in the US. Healthcare costs associated with the 0014 NSAIDs are a group of structurally diverse com treatment of skin cancers have been reported to be over 500 pounds used clinically for the Successful treatment of a million annual in the US. range of disorders that are associated with pain and/or US 2005/O124697 A1 Jun. 9, 2005 inflammation (including arthritic disorders). NSAIDs are chemopreventive agent for NMSC. Currently, no such treat known to inhibit the cyclooxygenase (“COX”) enzymes, ment exists, otherwise the recurrence rate would not be So which catalyse the conversion of arachidonic acid to the high.
Load more

Recommended publications
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]
  • Effects of Clofibric Acid on the Biliary Excretion of Benoxaprofen
    ORIGINAL ARTICLES Clinical Pharmaceutics Laboratory, Department of Pharmacy and Health Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan Effects of clofibric acid on the biliary excretion of benoxaprofen glucuronide and taurine conjugate in rats K. Okada, H. Kanoh, K. Mohri Received March 8, 2011, accepted April 15, 2011 Prof. Kiminori Mohri, Clinical Pharmaceutics Laboratory, Department of Pharmacy and Health Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose-shi, Tokyo 204-8588, Japan [email protected] Pharmazie 66: 777–783 (2011) doi: 10.1691/ph.2011.1031 Benoxaprofen (BOP) is a 2-methyl propionic acid derivative with anti-inflammatory activity. BOP has an asymmetric carbon, and receives chiral inversion from R to S in vivo. BOP is metabolized to glucuronide (BOP-G) and taurine conjugate (BOP-T). The configuration of BOP-G is mainly S, and that of BOP-T is R. Chiral inversion of R to S of the propionic acid moiety and amino acid conjugation of carboxyl compounds proceed via an acyl CoA intermediate. It is known that fibrates, used in hyperlipidemia, induce acyl CoA synthetase and increase CoA concentration. We administered racemic BOP (10 mg/kg body weight) to rats (CFA+ ) pre-administered clofibric acid (CFA, 280 mg/kg/day), and studied BOP, BOP-G, and BOP-T enantiomer concentrations in plasma and bile up to 12 h after administration. The findings were compared with those in rats (CFA-) that had not received CFA. Furthermore, we studied the amounts of BOP-G enantiomer produced by glucuronidation in vitro using microsomes pretreated with CFA.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Wo 2009/139817 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 19 November 2009 (19.11.2009) WO 2009/139817 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/4709 (2006.01) C07D 405/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) Number: International Application CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, PCT/US2009/002391 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 15 April 2009 (15.04.2009) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (25) Filing Language: English NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (26) Publication Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/045,142 15 April 2008 (15.04.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): SAR- GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, CODE CORPORATION [US/US]; Suite 505, 343 San- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, some Street, San Francisco, CA 94104 (US).
    [Show full text]
  • Pharmaceutical Co-Crystal Compositions of Celecoxib
    (19) & (11) EP 2 339 328 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.06.2011 Bulletin 2011/26 G01N 21/27 (2006.01) G01N 25/08 (2006.01) C07B 63/00 (2006.01) A61K 31/415 (2006.01) (2006.01) (2006.01) (21) Application number: 10193736.5 C07B 63/04 C07D 231/12 (22) Date of filing: 24.12.2003 (84) Designated Contracting States: • Remenar, Julius AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Framingham, MA 01701 (US) HU IE IT LI LU MC NL PT RO SE SI SK TR • Peterson, Matthew Hopkinton, MA 01748 (US) (30) Priority: 30.12.2002 US 437516 P • Almarsson, Orn 21.01.2003 US 441335 P Shrewsbury, MA 01545 (US) 28.02.2003 US 451213 P • Guzman, Hector 18.03.2003 US 456027 P Boston, MA 02118 (US) 21.03.2003 US 456608 P • Chen, Hongming 01.04.2003 US 459501 P Acton, MA 01720 (US) 20.06.2003 US 601092 • Oliveira, Mark 11.07.2003 US 486713 P Bedford, MA 01730 (US) 11.07.2003 US 487064 P 11.09.2003 US 660202 (74) Representative: Daniels, Jeffrey Nicholas 20.06.2003 PCT/US03/19574 Page White & Farrer 04.09.2003 PCT/US03/27772 Bedford House 16.09.2003 PCT/US03/28982 John Street London WC1N 2BF (GB) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 03808567.6 / 1 579 198 •Claims filed after the date of filing of the application/ after the date of receipt of the divisional application (71) Applicant: Transform Pharmaceuticals, Inc.
    [Show full text]
  • Inflammatory Drug
    Abbreviations used: AR(s), adverse hepatotoxicity, 17 reaction(s); ADR(s), adverse drug manufacturers, 9 reaction(s); NSAID(s), non-steroid anti­ amorfazone, trade mark names and inflammatory drug(s) manufacturers, 9 Amuno, generic name and manufacturer, 12 anaemia absorption interactions, drug, 180-1 aplastic, 83 acemetacin, trade mark names and report rate, 33 manufacturers, 8 haemolytic, 84-5 acetyl salicylic acid, see Aspirin in rheumatoid patients, inappropriate action, drug, ~ pharmacoactivity therapy, 250 activation (of drugs), 243-5, 246, 247 anaphylaxis/anaphylactoid reactions, 17, pathway, 244 81 Actol, generic name and manufacturer, 13 Anaprox, generic name and manufacturer, Actosal, generic name and manufacturer, 13 9 angioedema, 6 acyl-coenzyme A formation, 221-2 angiotensin-converting enzyme, 195, 196 adjuvant induced arthritis, ~ inhibitors arthritis function, 195 Af1oxan, generic name and manufacturer, NSAID interactions with, 195-200 14 animal(s) age see also elderly experimentation, ethics of, 267 gastrointestinal susceptibility re­ inter species differences in lated to, 164, 286-8 propionate chiral inversion, use of anti-arthritics correlated 222-3, 223 with, 152 Ansaid, generic name and manufacturer, aged, the, ~ elderly 11 agranulocytosis antacids, 292 incidence, 7, 100-2 passim effect on drug absorption, 180, 181 in Sweden, 66, 67 NSAID interactions with, 185, 193 pyrazolone-induced, 7, 99-104 anthranilic acid, relative safety, 18 analytical epidemiological anti-arthritic drugs, ~ antirheumatic studies, 101-3 drugs
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of - Medicines belonging to the ATC group M01 (Antiinflammatory and antirheumatic products) Table of Contents Page INTRODUCTION 6 DISCLAIMER 8 GLOSSARY OF TERMS USED IN THIS DOCUMENT 9 ACTIVE SUBSTANCES Phenylbutazone (ATC: M01AA01) 11 Mofebutazone (ATC: M01AA02) 17 Oxyphenbutazone (ATC: M01AA03) 18 Clofezone (ATC: M01AA05) 19 Kebuzone (ATC: M01AA06) 20 Indometacin (ATC: M01AB01) 21 Sulindac (ATC: M01AB02) 25 Tolmetin (ATC: M01AB03) 30 Zomepirac (ATC: M01AB04) 33 Diclofenac (ATC: M01AB05) 34 Alclofenac (ATC: M01AB06) 39 Bumadizone (ATC: M01AB07) 40 Etodolac (ATC: M01AB08) 41 Lonazolac (ATC: M01AB09) 45 Fentiazac (ATC: M01AB10) 46 Acemetacin (ATC: M01AB11) 48 Difenpiramide (ATC: M01AB12) 53 Oxametacin (ATC: M01AB13) 54 Proglumetacin (ATC: M01AB14) 55 Ketorolac (ATC: M01AB15) 57 Aceclofenac (ATC: M01AB16) 63 Bufexamac (ATC: M01AB17) 67 2 Indometacin, Combinations (ATC: M01AB51) 68 Diclofenac, Combinations (ATC: M01AB55) 69 Piroxicam (ATC: M01AC01) 73 Tenoxicam (ATC: M01AC02) 77 Droxicam (ATC: M01AC04) 82 Lornoxicam (ATC: M01AC05) 83 Meloxicam (ATC: M01AC06) 87 Meloxicam, Combinations (ATC: M01AC56) 91 Ibuprofen (ATC: M01AE01) 92 Naproxen (ATC: M01AE02) 98 Ketoprofen (ATC: M01AE03) 104 Fenoprofen (ATC: M01AE04) 109 Fenbufen (ATC: M01AE05) 112 Benoxaprofen (ATC: M01AE06) 113 Suprofen (ATC: M01AE07) 114 Pirprofen (ATC: M01AE08) 115 Flurbiprofen (ATC: M01AE09) 116 Indoprofen (ATC: M01AE10) 120 Tiaprofenic Acid (ATC:
    [Show full text]
  • Synthesis and Evaluation of Mutual Azo Prodrug of 5-Aminosalicylic Acid Linked to 2-Phenylbenzoxazole-2-Yl-5-Acetic Acid in Ulcerative Colitis
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis Jamal A Jilani1 Abstract: In this study, the syntheses of 4-aminophenylbenzoxazol-2-yl-5-acetic acid, Maha Shomaf2 (an analogue of a known nonsteroidal anti-inflammatory drug [NSAID]) and 5-[4-(benzo- Karem H Alzoubi3 xazol-2-yl-5-acetic acid)phenylazo]-2-hydroxybenzoic acid (a novel mutual azo prodrug of 5-aminosalicylic acid [5-ASA]) are reported. The structures of the synthesized compounds 1Department of Medicinal Chemistry 1 and Pharmacognosy, Jordan University were confirmed using infrared (IR), hydrogen-1 nuclear magnetic resonance ( H NMR), and of Science and Technology, Irbid, mass spectrometry (MS) spectroscopy. Incubation of the azo compound with rat cecal contents 2 Jordan; Department of Pathology, demonstrated the susceptibility of the prepared azo prodrug to bacterial azoreductase enzyme. Jordan University, Amman, Jordan; 3Department of Clinical Pharmacy, The azo compound and the 4-aminophenylbenzoxazol-2-yl-5-acetic acid were evaluated for Jordan University of Science and inflammatory bowel diseases, in trinitrobenzenesulfonic acid (TNB)-induced colitis in rats. Technology, Irbid, Jordan The synthesized diazo compound and the 4-aminophenylbenzoxazol-2-yl-5-acetic acid were found to be as effective as 5-aminosalicylic acid for ulcerative colitis.
    [Show full text]
  • Risk Assessment of Reactive Metabolites in Drug Discovery: a Focus on Acyl Glucuronides and Acyl-Coa Thioesters
    Risk Assessment of Reactive Metabolites in Drug Discovery: A Focus on Acyl Glucuronides and Acyl-CoA Thioesters The Delaware Valley Drug Metabolism Discussion Group 2017 Rozman Symposium HUMAN BIOTRANSFORMATION: THROUGH THE MIST Langhorne, PA, June 13, 2017 Mark Grillo, PhD Drug Metabolism & Pharmacokinetics MyoKardia South San Francisco, CA [email protected] CommercializationDrug Process Discovery Overview & Development Therapeutic Area/Disease Lead Selection & Product Strategy Market Readiness & Launch / Post-Launch Opportunity Assessment Pre-clinical Testing Development Regulatory Approval Lifecycle Management Hit-to- Lead Post- Discovery Screen Pre-clinical Phase 1 Phase 2 Phase 3 Filing Launch Lead Optimization Launch Preclinical Pharmacokinetics & Drug Metabolism Assays Target Selection & Validation Lead compound Selection Discovery Screen Hit-to-Lead Lead Optimization Optimize Pharmacokinetics Characterize Preclinical Candidate Liver microsomal stability Intrinsic clearance Membrane permeability Excretion balance Efflux/transport assays Definitive metabolite ID Plasma stability Higher species PK Rat PK Human PK prediction Protein binding Assess DDI Potential Blood to plasma ratio Competitive CYP IC50 Early DDI Assessment Time-dependent CYP inhibition Enzyme induction PXR activation Hepatocyte induction CYP inhibition CYP reaction phenotyping Detection and Assessment of Chemically-Reactive Metabolites 2 Circumstantial Evidence Links Reactive Metabolites to Adverse Drug Reactions • Toxicity is a frequent cause of drug withdrawal
    [Show full text]